Blueprint Medicines
BPMC
HK$1,007
Share price
0.12%
Change (1 day)
18.07%
Change (1 year)
Categories
Blueprint Medicines (BPMC) - Total debt
Total debt on the balance sheet as of March 2025 : HK$3.66 Billion
According to Blueprint Medicines 's latest financial reports the company's total debt is HK$3.66 Billion. A company’s total debt is the sum of all current and non-current debts.
Blueprint Medicines - Total debt on balance sheet (from 2014 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | HK$3.64 B | 40.24% |
| 2023-12-31 | HK$2.59 B | 37.08% |
| 2022-12-31 | HK$1.89 B | 118.06% |
| 2021-12-31 | HK$0.86 B | 25.06% |
| 2020-12-31 | HK$0.69 B | -7.04% |
| 2019-12-31 | HK$0.74 B | 552.83% |
| 2018-12-31 | HK$0.11 B | -17.92% |
| 2017-12-31 | HK$0.13 B | 141.75% |
| 2016-12-31 | HK$57.68 M | -34.05% |
| 2015-12-31 | HK$87.47 M | 24.72% |
| 2014-12-31 | HK$70.13 M | 215.91% |
| 2013-12-31 | HK$22.2 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Isoray
ISR | HK$3.07 M | -99.92% | 🇺🇸 USA |
 OPKO Health
OPK | HK$3.86 B | 5.61% | 🇺🇸 USA |
 Pacific Biosciences
PACB | HK$5.48 B | 49.80% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |